Stanley Hazen, M.D., Ph.D., chair of the Department of Cellular and Molecular Medicine at the Cleveland Clinic Lerner Research Institute, will present the ninth annual Meredith S. and John A. Oates Lectureship in Clinical Pharmacology on Nov. 5.
Hazen’s lecture, entitled “Gut Microbes as Participants and Therapeutic Targets in Cardiometabolic Disease,” will be delivered during Medicine Grand Rounds at 8 a.m. in room 208 Light Hall.
Hazen is the Jan Bleeksma Chair in Vascular Cell Biology and Atherosclerosis, the Leonard Krieger Chair in Preventive Cardiology, and head of the Section for Preventive Cardiology and Rehabilitation at the Cleveland Clinic.
He also is vice chair of Translational Research in the Lerner Research Institute, director of the Center for Cardiovascular Diagnostics and Prevention, and director of the Mass Spectrometry Core Facilities at the Cleveland Clinic.
Hazen’s research interests include understanding the role of inflammation and oxidant stress in the pathogenesis of atherosclerosis and other inflammatory diseases, and the role of intestinal microbiota in cardiometabolic disease.
His work has contributed to new understandings of inflammation in cardiovascular disease and development of new diagnostic and treatment tools. Hazen is listed as a co-inventor on multiple patents for his work in identifying patients at increased risk for cardiovascular disease, diagnosing asthma, and treating inflammation and associated complications.
The Oates lecture is named for John Oates, M.D., Thomas F. Frist Sr. Professor of Medicine, professor of Pharmacology and founding director of the Division of Clinical Pharmacology, and his wife, Meredith.
